EHA2026 | DREAMM-8: Early RRMM and sustained MRD-negativity subgroup analyses

During the European Hematology Association (EHA) 2026 Congress, June 11–14, 2026, Stockholm, SE, the Multiple Myeloma Hub spoke with Meral Beksaç, Istinye University Ankara Liv Hospital, Ankara, TR. We asked about the key findings from two subgroup analyses of the phase III DREAMM-8 trial in RRMM.

The first analysis explored outcomes among patients who received only one prior LoT, while the second examined outcomes in patients who achieved sustained MRD negativity.

This educational resource is independently supported by GSK. All content is developed by SES in collaboration with an expert steering committee. Funders are allowed no influence.

Hosted on Acast. See acast.com/privacy for more information.